PDGFRA and glioblastoma: Therefore, to deepen the comparison of GBM and GSCs, we decided to focus on copy number patterns of well-characterized genetic markers in primary GBMs that could be also exploited for the development of new treatments: EGFR, PDGFRA, MDM4, and MET amplification and CDKN2A, PTEN, and NFKB1 deletions (Table 3).